Evidence map›Paper›PMID 36062168›Full record

ReviewEvidence-based complementary and alternative medicine : eCAM2022

The Efficacy and Safety of Dingkun Pill in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Bao Jin, Yang Zhang, Zongyu Zhang, Guorong Yang, Yujia Pan, Liangzhen Xie, Jiarui Liu, Wenjuan Shen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bao JinDepartment of Obstetrics and Gynecology, Heilongjiang University of Chinese Medicine, Harbin 150040, China.ORCID https://orcid.org/0000-0002-3522-136X
Yang ZhangDepartment of Internal Medicine, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin 150040, China.ORCID https://orcid.org/0000-0001-9983-0263
Zongyu ZhangDepartment of Obstetrics and Gynecology, Heilongjiang University of Chinese Medicine, Harbin 150040, China.ORCID https://orcid.org/0000-0002-8202-3315
Guorong YangDepartment of Obstetrics and Gynecology, Heilongjiang University of Chinese Medicine, Harbin 150040, China.ORCID https://orcid.org/0000-0002-0795-2130
Yujia PanDepartment of Obstetrics and Gynecology, Heilongjiang University of Chinese Medicine, Harbin 150040, China.ORCID https://orcid.org/0000-0002-4658-8650
Liangzhen XieDepartment of Traditional Chinese Medicine, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin 150040, China.ORCID https://orcid.org/0000-0003-1375-1666
Jiarui LiuDepartment of Biology, College of Life Science and Technology, Guangxi University, Nanning 530004, China.ORCID https://orcid.org/0000-0002-6186-8212
Wenjuan ShenDepartment of Obstetrics and Gynecology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin 150040, China.ORCID https://orcid.org/0000-0002-6193-825X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Dingkun Pill (DKP) is a proprietary Chinese medicine that has been utilized for patients with gynecological diseases, and its clinical application has been widely accepted in China. However, the effects of DKP on reproduction and metabolism in women with polycystic ovary syndrome (PCOS) have never been systematically evaluated. Our objective was to evaluate the efficacy and safety of DKP in treating reproductive and metabolic abnormalities with PCOS. Methods: We searched in PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wanfang Database, VIP Database, and Chinese Biomedical Literature Database up until January 2022 to identify randomized controlled trials (RCTs). The methodological quality of the included RCTs was estimated using the Cochrane collaboration risk-of-bias instrument, and the meta-analysis was performed using RevMan. Results: A total of 22 RCTs (including 1994 participants) were identified. DKP, combined with ovulation-inducing drugs (OID) or combined oral contraceptives (COC) was superior to OID or COC alone in improving the pregnancy rate (relative risk (RR) 1.84, 95% CI 1.62 to 2.11 and RR 1.38, 95% CI 1.16 to 1.64, respectively), ovulation rate (RR 1.38, 95% CI 1.03 to 1.84 and RR 1.23, 95% CI 1.11 to 1.37, respectively), endometrial thickness (weighted mean difference (WMD) 2.50, 95% CI 1.91 to 3.09 and WMD 0.62, 95% CI 0.08 to 1.16, respectively), luteinizing hormone (WMD -1.93, 95% CI -2.80 to-.07 and WMD -1.79, 95% CI -2.66 to-0.92, respectively), and testosterone (standardized mean difference (SMD) -2.12, 95% CI -3.01 to-1.24 and SMD -1.21, 95% CI -1.64 to-0.78, respectively). DKP combined with COC led to a greater improvement in homeostasis model assessment- Conclusion: DKP shows promise in modifying reproductive and metabolic parameters in patients with PCOS and may be used as a primary choice in conventional or complementary therapies for PCOS. The quality of the evidence analyzed was suboptimal, and therefore, our results should be interpreted cautiously. More prospective large-scale and well-designed RCTs, as well as longer intervention durations are required in the future to draw more reliable conclusions.

Identifiers

PMID36062168
PMCPMC9433272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.